AMAL Therapeutics SA is a spin-off from the University of Geneva
active in cancer immunotherapy.
AMAL has developed a unique protein-based immunization
platform called KISIMA® providing activation signal to dendritic
cells simultaneously to priming both helper and killer cells for
various antigens and HLA restrictions. This first-in-class platform is
offering the opportunity to develop standardized and indicationtailored
The company’s lead product ATP128 is currently being developed
for metastatic and advanced colorectal cancer.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.